| P50 | author | Janja Marc | Q42815054 |
| | Nika Lovšin | Q92602299 |
| P2093 | author name string | Radko Komadina | |
| | Vid Mlakar | |
| | Janja Zupan | |
| | Klemen Kodrič | |
| | Tilen Kranjc | |
| P2860 | cites work | Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation | Q22253308 |
| | Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies | Q24289320 |
| | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | Control of RANKL gene expression | Q24619669 |
| | Targeting RANKL in metastasis | Q26849690 |
| | The role of estrogen and androgen receptors in bone health and disease | Q27008878 |
| | The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development | Q28142247 |
| | Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators | Q28143448 |
| | Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd | Q28512189 |
| | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 |
| | NF-Y is essential for the recruitment of RNA polymerase II and inducible transcription of several CCAAT box-containing genes | Q28590656 |
| | Essential role of beta-catenin in postnatal bone acquisition | Q28594492 |
| | Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture | Q34268288 |
| | Review and management of 46,XY disorders of sex development | Q34320156 |
| | Estimating prevalence of osteoporosis: examples from industrialized countries | Q34420847 |
| | Transcription factors in bone: developmental and pathological aspects | Q34735288 |
| | Sex determination in mammals--before and after the evolution of SRY. | Q34789293 |
| | Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region | Q35063276 |
| | Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers | Q35071128 |
| | Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer | Q35071181 |
| | c-Myb regulates matrix metalloproteinases 1/9, and cathepsin D: implications for matrix-dependent breast cancer cell invasion and metastasis | Q35887678 |
| | Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF | Q36325366 |
| | Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass | Q36372606 |
| | Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene | Q36550226 |
| | An estimate of the worldwide prevalence and disability associated with osteoporotic fractures | Q36597363 |
| | An enhancer 20 kilobases upstream of the human receptor activator of nuclear factor-kappaB ligand gene mediates dominant activation by 1,25-dihydroxyvitamin D3 | Q36629317 |
| | Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma | Q36732811 |
| | The human SRY transcript | Q36742596 |
| | Deletion of the Distal Tnfsf11 RL-D2 Enhancer That Contributes to PTH-Mediated RANKL Expression in Osteoblast Lineage Cells Results in a High Bone Mass Phenotype in Mice | Q36808470 |
| | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. | Q36860987 |
| | Contribution of gender-specific genetic factors to osteoporosis risk. | Q37165656 |
| | Sex differences in the association between adiponectin and BMD, bone loss, and fractures: the Rancho Bernardo study | Q37469372 |
| | CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression. | Q38345794 |
| | Mutations and sequence variants in the testis-determining region of the Y chromosome in individuals with a 46,XY female phenotype. | Q38346414 |
| | Vertebrate sex determination: evolutionary plasticity of a fundamental switch. | Q38626969 |
| | The mouse RANKL gene locus is defined by a broad pattern of histone H4 acetylation and regulated through distinct distal enhancers | Q39564377 |
| | RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. | Q39670403 |
| | Expression and characterization of c-Myb in prenatal odontogenesis | Q39728276 |
| | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone | Q39946634 |
| | PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells | Q40054780 |
| | Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats | Q40277043 |
| | Regulation of cancer cell migration and bone metastasis by RANKL. | Q40298349 |
| | Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro | Q40307786 |
| | Regulation of RANKL promoter activity is associated with histone remodeling in murine bone stromal cells | Q40511365 |
| | Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells | Q40706559 |
| | Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus | Q40820746 |
| | STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroi | Q40945774 |
| | Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study | Q41904942 |
| | c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt/β-Catenin/Axin2 Pathway. | Q42493372 |
| | Osteoprotegerin and rank ligand expression in prostate cancer | Q42502915 |
| | Gene delivery of c-myb increases bone formation surrounding oral implants | Q42816800 |
| | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study | Q42829926 |
| | c-Myb contributes to G2/M cell cycle transition in human hematopoietic cells by direct regulation of cyclin B1 expression | Q42924839 |
| | Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases | Q43011355 |
| | Osteoarthritic versus osteoporotic bone and intra-skeletal variations in normal bone: evaluation with µCT and bone histomorphometry. | Q43603196 |
| | Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter | Q44511491 |
| | Body composition changes with age have gender-specific impacts on bone mineral density. | Q45036051 |
| | The Wnt antagonist Dickkopf-1 mobilizes vasculogenic progenitor cells via activation of the bone marrow endosteal stem cell niche | Q46384559 |
| | Triglyceride metabolism in bone tissue is associated with osteoblast and osteoclast differentiation: a gene expression study | Q46488499 |
| | Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo | Q47616899 |
| | Role of c-Myb in chondrogenesis | Q50215738 |
| | The cooperation of CREB and NFAT is required for PTHrP-induced RANKL expression in mouse osteoblastic cells. | Q50636803 |
| | Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. | Q51054343 |
| | Diverse developing mouse lineages exhibit high-level c-Myb expression in immature cells and loss of expression upon differentiation. | Q52179311 |
| | The Relationship Between Bone Density and Incident Vertebral Fracture in Men and Women | Q57417256 |
| | Expression of bone resorption genes in osteoarthritis and in osteoporosis | Q60659190 |
| | Increased osteoclast development after estrogen loss: mediation by interleukin-6 | Q68188964 |
| | Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand | Q79181865 |
| P433 | issue | 8 | |
| P304 | page(s) | 1-16 | |
| P577 | publication date | 2019-08-14 | |
| P1433 | published in | Experimental and Molecular Medicine | Q15758292 |
| P1476 | title | Sex-determining region Y (SRY) attributes to gender differences in RANKL expression and incidence of osteoporosis | |
| P478 | volume | 51 | |